Jascayd Dosing
The recommended dosing regimen for Jascayd (nerandomilast) is 18 mg orally twice daily for both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). 1
Standard Dosing
- Standard dose: 18 mg orally twice daily
- Alternative dose: 9 mg orally twice daily (lower efficacy but still beneficial)
- Both doses demonstrated efficacy in reducing FVC decline compared to placebo, with the 18 mg twice daily dose showing superior results 1, 2, 3
Dose Modifications
When Taking Strong CYP3A Inhibitors
Reduce to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir), as these medications increase nerandomilast exposure and may increase adverse reaction risk 1
When Taking Pirfenidone
Maintain 18 mg twice daily when used with pirfenidone - do NOT reduce to 9 mg twice daily. Pirfenidone decreases nerandomilast exposure, and the 9 mg dose was ineffective when combined with pirfenidone in clinical trials 1
When Taking Nintedanib
No dose adjustment needed - standard 18 mg twice daily dosing is appropriate. Approximately 77.7% of IPF patients and 43.5% of PPF patients in pivotal trials were taking background nintedanib or pirfenidone 2, 3
Medications to Avoid
Avoid concomitant use with moderate or strong CYP3A inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, St. John's Wort), as these will decrease nerandomilast exposure and reduce efficacy 1
Clinical Considerations
Timing and Administration
- Nerandomilast is rapidly absorbed with peak concentrations at 0.5-1.25 hours post-dose 4
- Can be taken with or without food
- Steady state reached by day 7 of twice-daily dosing 4
Common Pitfalls
- Diarrhea management: Most common adverse event (41.3% with 18 mg, 31.1% with 9 mg vs 16.0% placebo), typically mild-to-moderate and occurring within first 3 months. Diarrhea led to discontinuation in only 4% of patients taking 18 mg with nintedanib and 1% without nintedanib 1
- Weight monitoring: Weight decrease occurred in 12-13% of patients on 18 mg dose; monitor regularly 1
- Drug interaction errors: Remember that pirfenidone requires maintaining the 18 mg dose, while strong CYP3A inhibitors require dose reduction to 9 mg 1
Special Populations
- Renal impairment: No specific dose adjustments provided in labeling; nerandomilast is excreted 11.9% unchanged in urine 4
- Hepatic impairment: No specific guidance provided
- Pregnancy: May increase risk of fetal loss based on animal data; advise patients of potential risks 1
The evidence strongly supports 18 mg twice daily as the optimal dose for most patients, with dose modification only for specific drug interactions 2, 3.